ArticleThe oncologist2018

A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.

S Lindsey Davis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.